BioSpace News Archive

Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will participate in select upcoming investor and scientific conferences. Details can be found below.

I-Mab (the “Company”) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics, today announced that a poster highlighting the mechanistic differentiation and preclinical research for uliledlimab (also known as TJD5) will be presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Dr. Ivor Royston , President and Chief Executive Officer of Viracta will present at the Oppenheimer 31 st Annual Healthcare Conference taking place virtually from March 16-18, 2021

Enzychem Lifesciences (KOSDAQ: 183490), a clinical-stage biopharmaceutical company developing innovative medicines to improve the lives of patients with cancer and inflammatory diseases, today announced that an Enzychem Lifesciences representative will be participating as a panelist at the 15 th New York Health Forum

VANCOUVER, BC, March 11, 2021 /PRNewswire/ - CRH Medical Corporation announces a startup joint venture where CRH owns a 51% interest in a gastroenterology anesthesia practice located in Largo, Florida.

Dermavant Sciences announced that an abstract containing interim analysis data from Dermavant’s PSOARING 3 long-term, open-label safety study for tapinarof for the treatment of psoriasis in adults will be presented in poster format during the upcoming Innovations in Dermatology Virtual Spring Conference 2021, held from March 16-20, 2021.

Tvardi Therapeutics (“Tvardi”) a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced the appointment of Michael Wyzga, former Chief Financial Officer of Genzyme, to its Board of Directors.

Annovis Bio, Inc., ANVS, today announced that Maria Maccecchini, PhD, Founder, President and CEO, will be attending the Q1 Virtual Investor Summit. Event Q1 Investor Summit Date March 23-25th, 2021 Presentation March 24th @ 11:30AM ET

- Dr. Hans-Peter Stoll is an interventional cardiologist and senior medical executive with 20 years of leadership experience who has demonstrated deep expertise in clinical strategy and execution. - Dr. Stoll supports and expands MCRA’s specialization in cardiology and clinical trial management globally.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2021.